| 前收市價 | 0.2000 |
| 開市 | 0.1000 |
| 買盤 | 0.0500 |
| 賣出價 | 0.3000 |
| 拍板 | 42.50 |
| 到期日 | 2024-06-21 |
| 今日波幅 | 0.1000 - 0.1000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 721 |
BenzingaEurope Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
On Thursday, the European Commission granted marketing authorization under exceptional circumstances and maintained orphan designation for Biogen Inc’s (NASDAQ:BIIB) Qalsody (tofersen) for amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 gene (SOD1-ALS). Qalsody is the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND). SOD1-ALS is an ultra-rare genetic form of ALS estimated to affe
ZacksThe Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics are part of the Zacks top Analyst Blog.
ZacksIonis (IONS), Biogen Down on Ending Development of ALS Drug
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
